Cardiff Oncology Reports First Patient Dosing in P-II Trial for Onvansertib + Irinotecan and 5-FU as a 2L Treatment for Metastatic Pancreatic Ductal Adenocarcinoma

 Cardiff Oncology Reports First Patient Dosing in P-II Trial for Onvansertib + Irinotecan and 5-FU as a 2L Treatment for Metastatic Pancreatic Ductal Adenocarcinoma

Cardiff Oncology Reports First Patient Dosing in P-II Trial for Onvansertib + Irinotecan and 5-FU as a 2L Treatment for Metastatic Pancreatic Ductal Adenocarcinoma

Shots:

  • The first patient has been dosed in a P-II study evaluating the safety & preliminary efficacy of onvansertib + Irinotecan and 5-FU in ~40 patients as a 2L treatment for metastatic PDAC who have failed 1L gemcitabine-based therapy across 6 sites in the US
  • The 1EPs of the study is ORR and 2EPs include DoR, m-OS, ORR in patients receiving more than two treatment cycles, DCS, and assessment of KRAS allelic burden in liquid biopsies as measured by ctDNA
  • The ongoing P-II trial of onvansertib + irinotecan and 5-FU for KRAS-mutated mCRC showed clinical benefit and improve outcomes. Additionally, the company is also expected the similar results in PDAC trial

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Cardiff Oncology

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post